Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases
OBJECTIVE: To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ. METHODS: We identified all patients with a...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989153/ https://www.ncbi.nlm.nih.gov/pubmed/33875975 http://dx.doi.org/10.1093/rap/rkab014 |
_version_ | 1783668903644233728 |
---|---|
author | Pham, Khanh Torres, Heidi Satlin, Michael J Goyal, Parag Gulick, Roy M |
author_facet | Pham, Khanh Torres, Heidi Satlin, Michael J Goyal, Parag Gulick, Roy M |
author_sort | Pham, Khanh |
collection | PubMed |
description | OBJECTIVE: To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ. METHODS: We identified all patients with a rheumatologic disease who were admitted with COVID-19 to two hospitals in New York City between 3 March 3 and 30 April 2020. Patients who received chronic HCQ prior to admission were matched 1:2 (±10 years of age) with patients who did not receive chronic HCQ. We compared demographics, comorbidities, HCQ dosages, concurrent medications, presentations and outcomes between the groups. RESULTS: There were 14 patients receiving HCQ and 28 matched control subjects. The median age of cases was 63 years [interquartile range (IQR) 43–73) and 60 years (IQR 41–75) for controls. Control subjects had a higher prevalence of pulmonary diseases (42.8%), diabetes (35.7%) and obesity (35.7%) than their case counterparts (28.6%, 14.3% and 7.1%, respectively). A higher proportion of cases than control subjects (50% vs 25%) reported the use of prednisone for their rheumatic conditions prior to admission. Despite these differences in baseline characteristics, univariate logistic regression revealed no statistically significant differences in the need for mechanical ventilation [OR 1.5 (95% CI 0.34, 6.38)] or in-hospital mortality [OR 0.77 (95% CI 0.13, 4.56)]. CONCLUSION: HCQ therapy in individuals with rheumatic conditions was not associated with less severe presentations of COVID-19 among hospitalized patients compared with individuals with rheumatic conditions not receiving HCQ. |
format | Online Article Text |
id | pubmed-7989153 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-79891532021-04-01 Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases Pham, Khanh Torres, Heidi Satlin, Michael J Goyal, Parag Gulick, Roy M Rheumatol Adv Pract Concise Report OBJECTIVE: To compare baseline characteristics, clinical presentations and outcomes of patients with rheumatic conditions requiring hospitalization for coronavirus disease 2019 (COVID-19) who received chronic HCQ with those who did not receive chronic HCQ. METHODS: We identified all patients with a rheumatologic disease who were admitted with COVID-19 to two hospitals in New York City between 3 March 3 and 30 April 2020. Patients who received chronic HCQ prior to admission were matched 1:2 (±10 years of age) with patients who did not receive chronic HCQ. We compared demographics, comorbidities, HCQ dosages, concurrent medications, presentations and outcomes between the groups. RESULTS: There were 14 patients receiving HCQ and 28 matched control subjects. The median age of cases was 63 years [interquartile range (IQR) 43–73) and 60 years (IQR 41–75) for controls. Control subjects had a higher prevalence of pulmonary diseases (42.8%), diabetes (35.7%) and obesity (35.7%) than their case counterparts (28.6%, 14.3% and 7.1%, respectively). A higher proportion of cases than control subjects (50% vs 25%) reported the use of prednisone for their rheumatic conditions prior to admission. Despite these differences in baseline characteristics, univariate logistic regression revealed no statistically significant differences in the need for mechanical ventilation [OR 1.5 (95% CI 0.34, 6.38)] or in-hospital mortality [OR 0.77 (95% CI 0.13, 4.56)]. CONCLUSION: HCQ therapy in individuals with rheumatic conditions was not associated with less severe presentations of COVID-19 among hospitalized patients compared with individuals with rheumatic conditions not receiving HCQ. Oxford University Press 2021-03-02 /pmc/articles/PMC7989153/ /pubmed/33875975 http://dx.doi.org/10.1093/rap/rkab014 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Concise Report Pham, Khanh Torres, Heidi Satlin, Michael J Goyal, Parag Gulick, Roy M Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases |
title | Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases |
title_full | Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases |
title_fullStr | Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases |
title_full_unstemmed | Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases |
title_short | Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases |
title_sort | failure of chronic hydroxychloroquine in preventing severe complications of covid-19 in patients with rheumatic diseases |
topic | Concise Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989153/ https://www.ncbi.nlm.nih.gov/pubmed/33875975 http://dx.doi.org/10.1093/rap/rkab014 |
work_keys_str_mv | AT phamkhanh failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases AT torresheidi failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases AT satlinmichaelj failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases AT goyalparag failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases AT gulickroym failureofchronichydroxychloroquineinpreventingseverecomplicationsofcovid19inpatientswithrheumaticdiseases |